Tamara Vanhaecke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5595288/publications.pdf

Version: 2024-02-01

394421 477307 1,047 50 19 29 citations g-index h-index papers 53 53 53 1411 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	E-Selectin-Dependent Inflammation and Lipolysis in Adipose Tissue Exacerbate Steatosis-to-NASH Progression via S100A8/9. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 151-171.	4.5	26
2	From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. Biomedicines, 2022, 10, 161.	3.2	4
3	Metabolic Signature of Ethanol-Induced Hepatotoxicity in HepaRG Cells by Liquid Chromatography–Mass Spectrometry-Based Untargeted Metabolomics. Journal of Proteome Research, 2022, 21, 1153-1166.	3.7	7
4	Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery. Cells, 2022, 11, 893.	4.1	7
5	Light triggered nanoscale biolistics for efficient intracellular delivery of functional macromolecules in mammalian cells. Nature Communications, 2022, 13, 1996.	12.8	10
6	End-user engineering of ontology-based knowledge bases. Behaviour and Information Technology, 2022, 41, 1811-1829.	4.0	3
7	Impact of the Revised European Tobacco Product Directive on the Quality of E-cigarette Refill Liquids in Belgium. Nicotine and Tobacco Research, 2021, 23, 227-234.	2.6	6
8	Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. Cell Biology and Toxicology, 2021, 37, 293-311.	5.3	25
9	Identification of flavouring substances of genotoxic concern present in e-cigarette refills. Food and Chemical Toxicology, 2021, 147, 111864.	3.6	14
10	An exploratory approach for an oriented development of an untargeted hydrophilic interaction liquid chromatography-mass spectrometry platform for polar metabolites in biological matrices. Journal of Chromatography A, 2021, 1637, 461807.	3.7	28
11	Infections at the nexus of metabolic-associated fatty liver disease. Archives of Toxicology, 2021, 95, 2235-2253.	4.2	14
12	Toxicity assessment of flavour chemicals used in e-cigarettes: current state and future challenges. Archives of Toxicology, 2021, 95, 2879-2881.	4.2	7
13	An overview of current practices for regulatory risk assessment with lessons learnt from cosmetics in the European Union. Critical Reviews in Toxicology, 2021, 51, 395-417.	3.9	8
14	Safer chemicals using less animals: kick-off of the European ONTOX project. Toxicology, 2021, 458, 152846.	4.2	33
15	Transcriptional Profile of Cytokines, Regulatory Mediators and TLR in Mesenchymal Stromal Cells after Inflammatory Signaling and Cell-Passaging. International Journal of Molecular Sciences, 2021, 22, 7309.	4.1	9
16	Derivation, characterisation and analysis of an adverse outcome pathway network for human hepatotoxicity. Toxicology, 2021, 459, 152856.	4.2	25
17	Direct reprogramming of somatic cells into induced hepatocytes: Cracking the Enigma code. Journal of Hepatology, 2021, 75, 690-705.	3.7	15

Opinion of the Scientific Committee on Consumer Safety (SCCS) – Final Opinion on propylparaben (CAS) Tj ETQqQ 0 0 rgBŢ /Overlock

#	Article	IF	Citations
19	The SCCS scientific advice on the safety of nanomaterials in cosmetics. Regulatory Toxicology and Pharmacology, 2021, 126, 105046.	2.7	5
20	Optimization of a liquid chromatography-ion mobility-high resolution mass spectrometry platform for untargeted lipidomics and application to HepaRG cell extracts. Talanta, 2021, 235, 122808.	5.5	18
21	A Jigsaw-Based End-User Tool for the Development of Ontology-Based Knowledge Bases. Lecture Notes in Computer Science, 2021, , 169-184.	1.3	3
22	Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation. Genes, 2021, 12, 3.	2.4	8
23	The SCCS Notes of Guidance for the testing of cosmetic ingredients and their safety evaluation, 11th revision, 30–31 March 2021, SCCS/1628/21. Regulatory Toxicology and Pharmacology, 2021, 127, 105052.	2.7	55
24	Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells, 2020, 9, 37.	4.1	85
25	Flow cytometric quantification of neutral lipids in a human skin stem cell-derived model of NASH. MethodsX, 2020, 7, 101068.	1.6	3
26	Screening of repeated dose toxicity data in safety evaluation reports of cosmetic ingredients issued by the Scientific Committee on Consumer Safety between 2009 and 2019. Archives of Toxicology, 2020, 94, 3723-3735.	4.2	6
27	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Archives of Toxicology, 2020, 94, 1151-1172.	4.2	28
28	COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?. Archives of Toxicology, 2020, 94, 1367-1369.	4.2	103
29	Facilitating Data Curation: a Solution Developed in the Toxicology Domain. , 2020, , .		1
30	Inflammation Alters the Secretome and Immunomodulatory Properties of Human Skin-Derived Precursor Cells. Cells, 2020, 9, 914.	4.1	10
31	Untargeted liquid chromatography-mass spectrometry metabolomics to assess drug-induced cholestatic features in HepaRGA® cells. Toxicology and Applied Pharmacology, 2019, 379, 114666.	2.8	9
32	Exposure of HepaRG Cells to Sodium Saccharin Underpins the Importance of Including Non-Hepatotoxic Compounds When Investigating Toxicological Modes of Action Using Metabolomics. Metabolites, 2019, 9, 265.	2.9	1
33	Transcriptomics data of a human inÂvitro model of non-alcoholic steatohepatitis exposed to elafibranor. Data in Brief, 2019, 25, 104093.	1.0	3
34	Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. Pharmacological Research, 2019, 144, 377-389.	7.1	24
35	Metabolomics profiling of steatosis progression in HepaRG $\hat{A}^{\text{@}}$ cells using sodium valproate. Toxicology Letters, 2018, 286, 22-30.	0.8	33
36	Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone. Toxicology Letters, 2018, 284, 184-194.	0.8	9

#	Article	IF	CITATIONS
37	Performance of In Silico Models for Mutagenicity Prediction of Food Contact Materials. Toxicological Sciences, 2018, 163, 632-638.	3.1	14
38	Comment to †Letter to the editor: Human-based systems: Mechanistic NASH modelling just around the corner?'. Pharmacological Research, 2018, 137, 282-283.	7.1	2
39	In vitro assessment of hepatotoxicity by metabolomics: a review. Archives of Toxicology, 2018, 92, 3007-3029.	4.2	55
40	Human-based systems: Mechanistic NASH modelling just around the corner?. Pharmacological Research, 2018, 134, 257-267.	7.1	38
41	Tailored liquid chromatography–mass spectrometry analysis improves the coverage of the intracellular metabolome of HepaRG cells. Journal of Chromatography A, 2017, 1487, 168-178.	3.7	20
42	Assaying Cellular Viability Using the Neutral Red Uptake Assay. Methods in Molecular Biology, 2017, 1601, 19-26.	0.9	45
43	Optimisation of in vitro sample preparation for LC-MS metabolomics applications on HepaRG cell cultures. Analytical Methods, 2017, 9, 3704-3712.	2.7	11
44	Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples. Data in Brief, 2016, 7, 1052-1057.	1.0	8
45	Toxicogenomics-based prediction of acetaminophen-induced liver injury using human hepatic cell systems. Toxicology Letters, 2016, 240, 50-59.	0.8	49
46	In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells. Archives of Toxicology, 2016, 90, 677-689.	4.2	24
47	Identification of potential biomarkers of hepatitis B-induced acute liver failure using hepatic cells derived from human skin precursors. Toxicology in Vitro, 2015, 29, 1231-1239.	2.4	4
48	Effects of Trichostatin A on drug uptake transporters in primary rat hepatocyte cultures. EXCLI Journal, 2015, 14, 567-76.	0.7	5
49	Human Skin-Derived Stem Cells as a Novel Cell Source for In Vitro Hepatotoxicity Screening of Pharmaceuticals. Stem Cells and Development, 2014, 23, 44-55.	2.1	48
50	Screening of repeated dose toxicity data present in SCC(NF)P/SCCS safety evaluations of cosmetic ingredients. Archives of Toxicology, 2012, 86, 405-412.	4.2	35